65 results
Page 2 of 4
S-3
EX-4.6
uasls73ps27 58uq
12 Aug 21
Shelf registration
5:04pm
S-3
EX-4.7
v0na5xw
12 Aug 21
Shelf registration
5:04pm
8-K
EX-99.1
m657zgcsn
12 Aug 21
Nkarta Reports Second Quarter 2021 Financial Results and Business Progress
4:19pm
8-K
EX-10.1
r6shv9zh
14 Jul 21
Entry into a Material Definitive Agreement
7:07am
8-K
EX-99.1
n1t8pt9h
14 Jul 21
Entry into a Material Definitive Agreement
7:07am
8-K
EX-99.1
fn5ez2q2qog7j2o oj4o
13 May 21
Nkarta Reports First Quarter 2021 Financial Results and Business Progress
4:18pm
8-K
EX-99.1
wsb6j532k9 3u
6 May 21
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
4:24pm
8-K
EX-99.1
hbs0g27bhaz
28 Apr 21
Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies
8:07am
8-K
EX-99.1
2bguo
25 Mar 21
Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress
12:00am
10-K
cjc1ii8d
25 Mar 21
Annual report
12:00am
8-K
EX-99.1
4013eg6daytbeskikaw
12 Nov 20
Nkarta Reports Third Quarter 2020 Financial Results
4:08pm
8-K
EX-99.2
fuzwb
12 Nov 20
Nkarta Reports Third Quarter 2020 Financial Results
4:08pm
10-Q
suj7ga al8o54pngjt
20 Aug 20
Quarterly report
4:51pm
8-K
EX-3.2
1uevyzricy6
14 Jul 20
Amendments to Articles of Incorporation or Bylaws
4:10pm
8-K
EX-3.1
ilkd i3j5bgtvbfr76
14 Jul 20
Amendments to Articles of Incorporation or Bylaws
4:10pm
424B4
55j0xiww 7t3u
10 Jul 20
Prospectus supplement with pricing info
9:35pm